Navigation Links
Abbott Study Examines Rates of Uveitis (Inflammation of the Eye) in Ankylosing Spondylitis Patients Treated with HUMIRA(R) (adalimumab)
Date:11/8/2007

Painful Eye Condition Can Occur in Up to 40 Percent of People with

Ankylosing Spondylitis (Spinal Arthritis)

ABBOTT PARK, Ill., Nov. 8 /PRNewswire-FirstCall/ -- A study of ankylosing spondylitis (AS) patients treated with Abbott's HUMIRA(R) showed a decrease in the rate of uveitis flares by approximately half compared to patients treated with placebo. Ankylosing spondylitis is an inflammatory disease of the spine, and may also be associated with other inflammatory diseases of the skin, eyes, and intestines. Uveitis, or inflammation of the eye, occurs in up to 40 percent of people with AS, and can lead to severe and painful symptoms, including eye damage and blindness. These data were presented today at the American College of Rheumatology Annual Scientific Meeting in Boston.

The RHAPSODY (Review of safety and effectiveness witH Adalimumab in Patients with active ankylosing SpOnDYlitis) trial was designed to examine the effectiveness of HUMIRA in treating the signs and symptoms of AS in patients with active disease despite previous standard treatment. The 1,250 patient trial also included a subset of patients (n=274) with uveitis. Results of the trial suggested that the number of uveitis flares was reduced in patients with active AS treated with HUMIRA.

In the prospective, multi-national, open-label trial, adult patients with active AS who had insufficient responses to prior non-steroidal anti-inflammatory drug (NSAID) therapy received open-label HUMIRA 40 mg subcutaneously every other week for 12 weeks. Patients with symptomatic uveitis at baseline and/or in the previous year received the same regimen for a total of 20 weeks. Evaluations of treatment effects were measured at weeks 2, 6, 12 and week 20, if applicable.

This analysis measured the number of acute flares during treatment with HUMIRA both for all patients in the trial and for patients with pre-known history of uveitis. The rate was calculated as flares p
'/>"/>

SOURCE Abbott
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Abbott to Present at Bear Stearns Healthcare Conference
2. The National Center for Missing & Exploited Children, Wal-Mart, and Abbott Host Child Safety Events
3. Dow Jones Sustainability Index Again Recognizes Abbott for Continued Leadership in Business, Environmental and Social Performance
4. Abbott Declares 335th Consecutive Quarterly Dividend
5. Abbott Again Honored as Top Company for Working Moms
6. Abbotts HUMIRA(R) (adalimumab) Honored With Prestigious Galen Prize for Innovation in Patient Care
7. Abbott Hosts Conference Call for Third-Quarter Earnings
8. Abbott Broadens Use of i-STAT Handheld Blood Analyzer with CLIA Waiver Granted by FDA for CHEM8+ Test Cartridge
9. Abbott Named One of the Best Companies for Hispanics by Hispanic Business Magazine
10. Abbott Again Honored as a Leader in Diversity
11. Abbott Researchers Target Neuronal Nicotinic Receptors for Treatment of Pain and Cognition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Health Day Reporter TUESDAY, Sept. ... are overweight or obese when diagnosed appear to face ... cancer, new research suggests. , , The finding didn,t ... the potential for developing other cancers associated with obesity. ... reported being overweight or obese prior to diagnosis had ...
(Date:9/30/2014)... WASHINGTON Legislation passed in 2003 to slow the ... government to treat Medicare patients has had no meaningful ... of researchers in the Journal of Clinical Oncology ... of outpatient chemotherapy to treat colorectal and lung cancers, ... oncologists prescribe those drugs following the implementation of the ...
(Date:9/30/2014)... 2014 Research by UC Irvine immunologists reveals new ... on a vital process that determines how the body,s ... version of Nature Immunology , neurology professor Dr. ... for Immunology colleagues describe a critical mechanism underlying how ... bloodstream. , A T cell is a type of ...
(Date:9/30/2014)... Las Vegas, NV (PRWEB) September 30, 2014 ... by certified nutrition specialist and best-selling author Mike Geary that ... and totally transform their body into a fat-burning machine in ... Michaels, prompting an investigative review. , “In our culture ... it can be hard to decipher what is really fact ...
(Date:9/30/2014)... NY (PRWEB) September 30, 2014 ... hosted its annual “In Celebration” gala, honoring three ... nonprofit’s mission of striving to provide extraordinary and ... families facing a serious or life-limiting illness. , ... Club in Rye, NY and recognized William (Bill) ...
Breaking Medicine News(10 mins):Health News:Obesity Tied to Higher Cancer Risk for Colon Cancer Survivors 2Health News:Obesity Tied to Higher Cancer Risk for Colon Cancer Survivors 3Health News:Landmark Medicare law had little impact on reducing chemotherapy cost 2Health News:UCI study uncovers important process for immune system development 2Health News:Fat Burning Kitchen: Review Exposes Mike Geary’s 24-Hour Diet Transformation for Helping the Body Burn Fat Through a Natural Diet 2Health News:Fat Burning Kitchen: Review Exposes Mike Geary’s 24-Hour Diet Transformation for Helping the Body Burn Fat Through a Natural Diet 3Health News:Hospice & Palliative Care of Westchester Honors Outstanding Individuals at Annual ‘In Celebration’ Gala 2
... levels influence heart disease risk , , SUNDAY, Jan. 13 ... influence the risk of heart disease, have been identified ... three countries. , "I would predict that some of ... said the study,s senior author, Goncalo Abecasis, an associate ...
... Driving Global Breast Cancer Leader,s Promise ... Cancer Forever, ATLANTA, Jan. 12 Hala Moddelmog, president ... leader in the fight to end breast,cancer forever, today was ... Awards event in Atlanta with a ,High Heels in High,Places, ...
... Mandate Weakens After SEIU Contributes $450K to Prop ... ... "mean" or people will not be compelled to buy health insurance under the,Massachusetts ... financial projections for a similar plan pending in,California., As reported in the ...
... Department of,Environmental Protection is helping with efforts to ... 42-inch pipe ruptured Thursday evening between the city,s ... Island wastewater treatment plant.,The estimated 10 million gallons ... the treatment plant are, temporarily, being discharged into ...
... and lifestyle are at root of reduced risk, , , FRIDAY, Jan. ... your blood may reduce your risk of stroke, new research suggests. ... in their blood had a 42 percent lower risk of stroke ... is in the January issue of The American ...
... With a continued focus on,quality and efficiency ... focus on opportunities for streamlining processes to,maximize ... for,manufacturing organizations, the majority of the benchmark ... could provide several,worthwhile benefits, as found in ...
Cached Medicine News:Health News:Seven New Cholesterol Genes Discovered 2Health News:Seven New Cholesterol Genes Discovered 3Health News:Susan G. Komen for the Cure's CEO Hala Moddelmog Earns 'High Heels in High Places' Recognition at 2008 Trumpet Awards 2Health News:Susan G. Komen for the Cure's CEO Hala Moddelmog Earns 'High Heels in High Places' Recognition at 2008 Trumpet Awards 3Health News:MA Proponent of Health Insurance Mandate Says 'Mean' Penalties Needed to Force People to Buy Insurance 2Health News:Vitamin C May Play Role in Stroke Prevention 2Health News:Vitamin C May Play Role in Stroke Prevention 3Health News:Manufacturing Organizations Identify Efficiencies in Maintenance Functions 2
(Date:9/30/2014)... -- Georgia-Pacific Professional is a leading provider of hygienic ... range of away from home applications. Building on ... including hospitals, long-term care facilities, surgical centers and ... products and solutions to the dental community. ... control in the dental office," said Sean ...
(Date:9/30/2014)... BURLINGTON, Mass. , Sept. 30, 2014 /PRNewswire/ ... of U.S. patient-level claims data, anemic chronic kidney ... with their erythropoiesis-stimulating agent (ESA) medication. In addition, ... Janssen,s Procrit. Other key findings ... in Nephrology: An Analysis of Erythropoiesis Stimulating Agents ...
(Date:9/30/2014)... Sept. 30, 2014   Acutus Medical, ... invasive real-time 3D Cardiac Chamber Imaging and Dipole Density ... / or sustain complex cardiac arrhythmias, including atrial fibrillation, ... continue developing its imaging/mapping system as well as bring ... allow Acutus Medical to complete work on the AcQMap ...
Breaking Medicine Technology:Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 2Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 3Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 2Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 3Acutus Medical, Inc. Completes Additional $26.2M Series B Financing to Fund Portfolio Expansion 2Acutus Medical, Inc. Completes Additional $26.2M Series B Financing to Fund Portfolio Expansion 3
... 23 OrbusNeich today announced that six-month follow-up ... and efficacy of the company,s Genous Bio-engineered R ... the treatment of de novo coronary artery disease. ... University of Ulm, Germany, principal investigator of the ...
... DEERFIELD, Ill. and LONDON, Sept. 23 Following today’s ... and the European Medicines Agency (EMA) for rosiglitazone in ... and Takeda Pharmaceuticals Europe Limited (“Takeda”) underscore the company’s ... medications, and to the millions of people living with ...
Cached Medicine Technology:OrbusNeich's Genous™ Bio-engineered R stent™ Shows Favorable Safety Profile and Clinical Outcomes in Combination with Paclitaxel-Coated Balloon for De Novo Coronary Artery Disease 2OrbusNeich's Genous™ Bio-engineered R stent™ Shows Favorable Safety Profile and Clinical Outcomes in Combination with Paclitaxel-Coated Balloon for De Novo Coronary Artery Disease 3Takeda Responds to Announcement about Suspension of Rosiglitazone Marketing Authorization in Europe and Restrictions in the U.S. 2Takeda Responds to Announcement about Suspension of Rosiglitazone Marketing Authorization in Europe and Restrictions in the U.S. 3Takeda Responds to Announcement about Suspension of Rosiglitazone Marketing Authorization in Europe and Restrictions in the U.S. 4
1.25 mm x 2.5 mm blade. 135 degrees back scratcher. Round handle....
10 mm wide tip....
Large. Double-ended. 3 mm pointed end and 5 mm angled end....
9 mm wide tip. Designated most popular model or size....
Medicine Products: